36 CHAPTER 3 Myocardial infarctiona n (%) 523 (9.2) 374 (8.0) 81 (11.9) 47 (11.3) 34 (12.8) Renal impairment n (%) 620 (10.7) 414 (8.8) 123 (17.9) 58 (13.9) 65 (24.4) COPD n (%) 643 (11.1) 487 (10.3) 97 (14.1) 53 (12.7) 44 (16.3) Risk factors BMI in kg/m2 median (IQR) 27.5 (24.6-30.9) 27.5 (24.6-30.9) 27.2 (24.5-30.5) 27.2 (24.7-30.5) 26.9 (24.1-30.4) Medication Digoxin n (%) 112 (1.9) 19 (0.4) 58 (8.4) 12 (2.9) 46 (17.0) Anti-arrhythmic drugs - class I n (%) 28 (0.5) 6 (0.1) 12 (1.7) 0 (0.0) 12 (4.4) Anti-arrhythmic drugs - class III n (%) 110 (1.9) 41 (0.9) 24 (3.5) 5 (1.2) 19 (7.0) Anti-arrhythmic drugs - class IV n (%) 64 (1.1) 39 (0.8) 15 (2.2) 5 (1.2) 10 (3.7) Beta blockers n (%) 1,562 (27.0) 1,028 (21.8) 308 (44.5) 136 (32.4) 172 (63.5) Antihypertensive drugsb n (%) 2,575 (44.6) 1,913 (40.6) 397 (57.4) 204 (48.6) 192 (70.8) Platelet inhibitors n (%) 1,270 (22.0) 1,100 (23.4) 139 (20.1) 111 (26.4) 28 (10.3) Anticoagulants n (%) 779 (13.5) 219 (4.7) 284 (41.0) 59 (14.0) 224 (82.7) Antidiabetic drugs n (%) 1,105 (19.1) 894 (19.0) 141 (20.4) 73 (17.4) 67 (24.7) Physical examination, biomarkers (at the start of hospital admission) Temperature in °C median (IQR) 37.8 (37.0-38.5) 37.8 (37.0-38.6) 37.7 (37.0-38.5) 37.7 (37.0-38.5) 37.7 (36.9-38.4) C-reactive protein in mg/L median (IQR) 76.0 (31.0-144.0) 74.0 (29.0-141.0) 95.0 (45.0-170.0) 110.0 (56.0-180.0) 76.0 (31.0-135.5) White blood cell count x109/L median (IQR) 6.8 (5.0-9.3) 6.8 (5.0-9.2) 6.8 (5.0-9.9) 7.1 (5.0-10.5) 6.3 (4.9-8.8) a ST-elevation myocardial infarction or non-ST-elevation myocardial infarction. b Aldosterone antagonists, angiotensin II receptor blockers, angiotensin converting enzyme inhibitors, calcium channel blockers, diuretics. AF: atrial fibrillation; AFL: atrial flutter; AV: atrioventricular; BMI: body mass index; COPD: chronic obstructive pulmonary disease; IQR: interquartile range; n: number.
RkJQdWJsaXNoZXIy MTk4NDMw